Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 102 |
| Active Pipeline (Recruiting Now) | 49 (40) |
| Completed vs Stopped Early | 7 / 0 (0.0%) |
| Median Closed Actual Enrollment | 84 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Chinese PLA General Hospital | Beijing | 35 |
| Xuanwu Hospital Capital Medical University | Beijing, Beijing Municipality | 2 |
| China-Japan Friendship Hospital | Beijing, Beijing Municipality | 2 |
Explore interactive annual charts and M&A subsidiary rollups in the Chinese PLA General Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.